Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer
The Journal of Clinical Pharmacology · 2025-07 · 65 (7) · 873-884
DOI: 10.1002/jcph.70001 ↗At a glance
Klinische Studie (Phase I) in The Journal of Clinical Pharmacology, published online on 2025-02-19. Written by Xiaofei Zhou and 10 co-authors. Institution: Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA. Major MEDLINE topics: Antineoplastic Agents, Benzofurans, Colorectal Neoplasms, Protein Kinase Inhibitors. Cited 10 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Takeda Pharmaceuticals U.S.A., Inc., HUTCHMED, Takeda Pharmaceuticals U.S.A..
Abstract (original language)
Fruquintinib is a selective, oral tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors 1, 2, and 3, which is approved for patients with previously treated metastatic colorectal cancer regardless of biomarker status. This population pharmacokinetic (PK) analysis characterized sources of interpatient variability on the PK of fruquintinib and its major metabolite M11 using data from 557 subjects who received fruquintinib in five phase I/Ib studies and the FRESCO‐2 phase III study. The integrated model was a one‐compartment model with first‐order absorption, lag time in absorption, and linear elimination for fruquintinib and a one‐compartment model with linear elimination for M11. The half‐life of fruquintinib and M11 were estimated to be 43.2 and 54 h, respectively. Fruquintinib PK demonstrated dose proportionality. Fruquintinib oral clearance and apparent volume of distribution (V/F) increased with increasing body weight. Fruquintinib absorption rate constant was 60.7% lower with concurrent use of proton‐pump inhibitors (PPIs), and fruquintinib V/F was 9.08% lower in healthy subjects versus patients with cancer. Magnitudes of the covariate effects of body weight, concurrent use of PPIs, and health status on fruquintinib exposures were estimated to be
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
- HUTCHMED International Corporation, Florham Park, NJ, USA.
- Certara, Radnor, PA, USA.
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Division of Oncology, Washington University, St. Louis, MO, USA.
- Department of Oncology, Tongji University Shanghai East Hospital, Shanghai, China.
ORCID profiles: Adekemi Taylor
Funding
- Takeda Pharmaceuticals U.S.A., Inc.
- HUTCHMED
- Takeda Pharmaceuticals U.S.A.
Cite
APA
Zhou, X., Yang, X., Grinshpun, B., Taylor, A., Strong, L., Dasari, A., Wang-Gillam, A., Li, J., Xu, R. H., Gupta, N., & Chien, C. (2025). Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer. The Journal of Clinical Pharmacology, 65(7), 873-884. https://doi.org/10.1002/jcph.70001
Vancouver
Zhou X, Yang X, Grinshpun B, Taylor A, Strong L, Dasari A, et al. Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer. The Journal of Clinical Pharmacology. 2025;65(7):873-884. doi:10.1002/jcph.70001
BibTeX
@article{Zhou2025,
author = {Zhou, Xiaofei and Yang, Xiaoyan and Grinshpun, Boris and Taylor, Adekemi and Strong, Laura and Dasari, Arvind and Wang-Gillam, Andrea and Li, Jin and Xu, Rui-Hua and Gupta, Neeraj and Chien, Caly},
title = {Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
volume = {65},
number = {7},
pages = {873--884},
doi = {10.1002/jcph.70001}
}
EUVIMED